Overview

• CEOs of major pharmaceutical firms, including Novartis, Sanofi, AstraZeneca, and Bayer, call on the EU to align drug prices with U.S. levels to attract investment and sustain innovation.
• Companies argue that EU price caps, austerity measures, and trade tensions are eroding Europe's biopharma competitiveness and market appeal.
• Roche has committed $50 billion to U.S. investments over five years, with other firms like Novartis, Eli Lilly, and Johnson & Johnson also announcing significant U.S. expansions.
• Pharma leaders emphasize that Europe spends a smaller share of GDP on innovative medicines compared to the U.S., risking its ability to protect public health and maintain R&D capacity.
• The Trump administration's push to lower U.S. drug prices and potential tariff threats add pressure, further accelerating the redirection of investments away from Europe.